Navigation Links
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Date:3/31/2009

locally in the vagina. No SERMs that are currently approved and marketed in the United States have been shown to have beneficial effects on vaginal tissue and none are approved for use in treating vaginal symptoms.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in clinical development and an advanced preclinical program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta-HSD enzymes. In Europe, QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, located in Turku, Finland. For press releases and other Company information, please visit www.quatrx.com.


'/>"/>
SOURCE QuatRx Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today ... will present at the Jefferies 2015 Global Healthcare Conference in ... on Monday, June 1, 2015. The conference ... listen only Webcast. To listen, please go to: http://ir.unilife.com/events.cfm ... for those unable to listen live. ...
(Date:5/28/2015)... MOUNTAIN VIEW, Calif. , May 28, 2015 ... healthcare informatics market, Frost & Sullivan recognizes ... Frost & Sullivan Award for Company of the ... effort to take HCM to the next level ... highly strategic acquisitions and followed them up with ...
(Date:5/28/2015)... 28, 2015  Freedom Meditech, Inc., a medical device ... from current blood-based standards to early and non-invasive detection, ... in a Series C financing. The company seeks to ... since founded. The company has also appointed Mr. ... member of the company,s board of directors. Mr. Gerace ...
Breaking Medicine Technology:Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 2Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 3Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 4Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 5Freedom Meditech Raises $4.8 Million and Appoints John Gerace as Chief Executive Officer 2Freedom Meditech Raises $4.8 Million and Appoints John Gerace as Chief Executive Officer 3Freedom Meditech Raises $4.8 Million and Appoints John Gerace as Chief Executive Officer 4
... LONDON and CRANBURY, N.J., Oct. 29 GlaxoSmithKline PLC ... today announced a definitive agreement to develop and commercialize ... for the treatment of Fabry disease, a rare inherited ... receive an exclusive worldwide license to develop, manufacture and ...
... Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will ... be held November 10-12, 2010 at the Arizona Biltmore Hotel ... scheduled to present an overview of the Company and its ... 2010. To listen to the audio web cast ...
Cached Medicine Technology:GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 2GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 3GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 4GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 5GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 6Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 3
(Date:5/28/2015)... (PRWEB) May 28, 2015 Healthpointe ... will now be offering Echocardiography Examinations to patients ... performed by renowned Qualified Medical Examiner and licensed ... echocardiography test is a non-invasive and cost-effective approach ... are critically ill or have undergone surgery. ...
(Date:5/28/2015)... TX (PRWEB) May 28, 2015 Dr. ... cosmetic surgeons , has announced that the new Houston ... The American Association of Accreditation of Ambulatory Surgery Facilities ... surgery center . , According to Dr. Vitenas, ... meeting the standards of a Class C ambulatory surgery ...
(Date:5/28/2015)... Hexagon Geospatial is pleased to announce ... of engineering, spatial data and mapping services, is using ... point clouds for urban change assessments in Bernalillo County, ... BHI Spatial Data Division implemented a countywide approach to ... Collected by a variety of different digital aerial camera ...
(Date:5/28/2015)... Westport, CT (PRWEB) May 28, 2015 ... mobile monitoring software, announced their partnership with ... their kids’ online activity. The partnership ... programs with WebWatcher’s comprehensive parental monitoring software ... Detective Rich Wistocki, BeSure Consulting's passion is ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Ask not what ... amazing things you can do with your racquet. With the ... artist Stefan Bojic, who brings his astonishing tricks and unique ... In a series of videos, the trick artist playfully demonstrates ... coordination skills in a fun way, but also challenges tennis ...
Breaking Medicine News(10 mins):Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 3Health News:WebWatcher Partners with BeSure Consulting 2Health News:WebWatcher Partners with BeSure Consulting 3Health News:Tennis Artist Baffles Novak Djokovic - HEAD Launches Trick Shot Campaign “Frame & Play” 2
... ... nation to go orange and move it to end multiple sclerosis, a disease where someone is newly ... and the state of MS research aptly coincide. Move it to create a world free of ... New York, NY (Vocus) March 8, 2010 ...
... ... ... ... ...
... ... ... , ... , ...
... ... the Bedroom and Beyond , ... San Francisco (PRWEB) March 8, 2010 -- Good Vibrations, the legendary San ... Project as part of their corporate giving initiative, GiVe. , , ,This spring, ...
... ... tenants and users of commercial real estate. , ... (PRWEB) March 8, 2010 -- According ... representation , most commercial tenants have received 2009 expense reconciliation statements of operating ...
... 8, 2010 University of Utah engineers developed a computer-controlled, motorized ... precisely control scalpels, brushes and tools over a wider area than ... "We,ve invented a ... people in performing precision tasks with their hands such as surgery, ...
Cached Medicine News:Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 2Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 3Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 4Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 5Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 6Health News:100 Day Countdown to the World Congress of Cardiology Scientific Sessions 2010 2Health News:100 Day Countdown to the World Congress of Cardiology Scientific Sessions 2010 3Health News:Survey Reveals Health Insurance and Access to Care Not So Closely Linked 2Health News:Survey Reveals Health Insurance and Access to Care Not So Closely Linked 3Health News:Survey Reveals Health Insurance and Access to Care Not So Closely Linked 4Health News:Survey Reveals Health Insurance and Access to Care Not So Closely Linked 5Health News:Good Vibrations Announces New Donation Partner: Global Justice Ecology Project 2Health News:Good Vibrations Announces New Donation Partner: Global Justice Ecology Project 3Health News:Lease Audits Reduce Operating Costs 2Health News:Lease Audits Reduce Operating Costs 3Health News:A high-tech handrest 2Health News:A high-tech handrest 3Health News:A high-tech handrest 4Health News:A high-tech handrest 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: